National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 9) (No. PB 78 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L01291

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 78 of 2014
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 9)
 
National Health Act 1953
___________________________________________________________________________
 
I, Tony Wynd, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
 
Dated 23 September 2014
 
 
 
 
 
 
 
 
 
 
 
 
TONY WYND
Acting Assistant Secretary
Pharmaceutical Access Branch       
Pharmaceutical Benefits Division
Department of Health
 
___________________________________________________________________
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.9).
 
(2)                This Instrument may also be cited as PB 78 of 2014.
2             Commencement
                This Instrument commences on 1 October 2014.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]     Schedule 1, Part 1 after the entry for Epirubicin;
insert:
Eribulin
Solution for I.V. injection containing eribulin mesilate 1 mg in 2 mL
Injection
Halaven
EI
MP
C4646 C4649
D
 
[2]     Schedule 1, Part 2 after the entry for Epirubicin;
insert:
Eribulin
3
13
 
[3]     Schedule 3, Responsible Person codes, after entry for EA:
insert:
EI
Eisai Australia Pty Ltd
 73 117 970 993
 
[4]     Schedule 4, after the entry for Doxorubicin ‑ Pegylated Liposomal;
insert in the columns in the order indicated:
 
Eribulin
C4646
 
Locally advanced or metastatic breast cancer
Patient must have progressive disease,
Patient must have failed at least two prior chemotherapeutic regimens for this condition,
The treatment must be the sole PBS-subsidised therapy for this condition.

Compliance with Authority Required procedures

 
C4649
 
Locally advanced or metastatic breast cancer
Patient must have progressive disease,
Patient must have failed at least two prior chemotherapeutic regimens for this condition,
The treatment must be the sole PBS-subsidised therapy for this condition.

Compliance with Authority Required procedures - Streamlined Authority Code 4649